Infusion Partners, LLC

CLOSEOUT LETTER Infusion Partners, LLC MARCS-CMS 575451 — January 26, 2022 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: UPS Next Day Product: Drugs Recipient: Recipient Name Michael A. Curtis Recipient Title Senior Manager of Operations Infusion Partners, LLC 4137 Boardman Canfield Rd Ste L104 Canfield , OH 44406-8087 United States Issuing Office: Division of Pharmaceutical Quality Operations III United States Dear Mr. Curtis: The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter [Case # 575451; dated March 20, 2019]. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter. You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. Sincerely, /S/ Nicholas F. Lyons Director of Compliance Office of Pharmaceutical Quality Operations, Division III Content current as of: 02/11/2022 Regulated Product(s) Drugs